ORIC PHARMACEUTICALS

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

25 ноя 2024 16:15:00 Источник Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04 ноя 2024 16:15:00 Источник Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 ноя 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 окт 2024 16:15:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 окт 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 сен 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

26 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

12 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

05 авг 2024 16:15:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 авг 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

16 июл 2024 16:59:15 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 июл 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 июн 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

29 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

06 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

15 апр 2024 16:15:00 Источник Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire